Last reviewed 2026-04-20 · How we verify

Selzentry

At a glance

Approved indications

• CCR5 Tropic Drug Resistant HIV Infection

Common side effects

• Upper respiratory tract infection
• Pyrexia
• Herpes infection
• Appetite disorders
• Dizziness/postural dizziness
• Sinusitis
• Bronchitis
• Joint-related signs and symptoms
• Paresthesias and dysesthesias
• Constipation
• Sensory abnormalities
• Pain and discomfort

Serious adverse events

• Syncope
• Orthostatic hypotension

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• Antiviral Clinical Trial for Long Covid-19 (PHASE2)
• Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
• This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction (PHASE2)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (NA)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.